Your browser is no longer supported. Please, upgrade your browser.
Entasis Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-1.25 Insider Own39.70% Shs Outstand41.11M Perf Week21.22%
Market Cap177.42M Forward P/E- EPS next Y-1.02 Insider Trans131.94% Shs Float15.18M Perf Month43.89%
Income-44.60M PEG- EPS next Q-0.30 Inst Own11.00% Short Float2.22% Perf Quarter30.00%
Sales- P/S- EPS this Y37.00% Inst Trans-17.25% Short Ratio1.74 Perf Half Y83.90%
Book/sh1.29 P/B2.92 EPS next Y13.60% ROA-71.90% Target Price6.00 Perf Year66.81%
Cash/sh- P/C- EPS next 5Y- ROE-84.10% 52W Range1.58 - 3.88 Perf YTD52.63%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-2.83% Beta-
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low138.61% ATR0.25
Employees47 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)80.92 Volatility10.57% 7.91%
OptionableNo Debt/Eq0.00 EPS Q/Q62.70% Profit Margin- Rel Volume1.02 Prev Close3.75
ShortableYes LT Debt/Eq0.00 EarningsAug 12 BMO Payout- Avg Volume194.12K Price3.77
Recom1.80 SMA2026.19% SMA5041.70% SMA20047.57% Volume197,473 Change0.53%
Sep-09-20Initiated Cantor Fitzgerald Overweight $5
Jul-13-20Initiated ROTH Capital Buy $9
Sep-23-21 04:05PM  
Sep-15-21 04:01PM  
Sep-09-21 08:00AM  
Aug-14-21 05:54AM  
Aug-11-21 04:05PM  
Aug-10-21 08:00AM  
Aug-05-21 04:01PM  
Aug-04-21 04:05PM  
Jul-27-21 08:00AM  
Jul-14-21 08:00AM  
Jul-01-21 08:00AM  
Jun-18-21 08:00AM  
May-05-21 04:05PM  
May-03-21 04:05PM  
Mar-23-21 08:00AM  
Mar-13-21 02:06AM  
Jan-26-21 08:00AM  
Jan-07-21 08:00AM  
Dec-01-20 01:52AM  
Nov-17-20 08:00AM  
Nov-05-20 04:05PM  
Oct-14-20 08:00AM  
Oct-08-20 08:32AM  
Sep-10-20 08:00AM  
Aug-28-20 08:00AM  
Aug-06-20 04:05PM  
Aug-05-20 08:00AM  
Jul-13-20 10:05AM  
Jul-06-20 08:00AM  
Jun-22-20 09:48AM  
Jun-18-20 08:00AM  
Jun-11-20 04:05PM  
May-18-20 11:34AM  
May-07-20 04:05PM  
Apr-22-20 04:05PM  
Mar-13-20 07:46AM  
Mar-11-20 04:05PM  
Dec-19-19 09:49AM  
Nov-24-19 01:56PM  
Nov-14-19 07:30AM  
Oct-30-19 04:05PM  
Oct-29-19 08:30AM  
Oct-03-19 04:01PM  
Oct-01-19 10:07AM  
Sep-30-19 01:00AM  
Sep-19-19 11:56AM  
Sep-03-19 08:00AM  
Aug-12-19 07:30AM  
Aug-06-19 08:00AM  
Jul-01-19 09:13AM  
Jun-27-19 08:00AM  
Jun-24-19 08:00AM  
Jun-20-19 11:13AM  
Jun-18-19 04:01PM  
Jun-13-19 08:00AM  
Jun-10-19 08:00AM  
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate containing zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Innoviva, Inc.10% OwnerJun 11Buy2.006,268,97512,537,95010,000,000Jun 11 05:39 PM
Innoviva, Inc.10% OwnerMay 03Buy2.003,731,0257,462,0503,731,025May 20 02:39 PM